Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Epithelial Yap/Taz are required for functional alveolar regeneration following acute lung injury
Gianluca T. DiGiovanni, … , Jonathan A. Kropski, Jason J. Gokey
Gianluca T. DiGiovanni, … , Jonathan A. Kropski, Jason J. Gokey
Published September 7, 2023
Citation Information: JCI Insight. 2023;8(19):e173374. https://doi.org/10.1172/jci.insight.173374.
View: Text | PDF
Research Article Pulmonology

Epithelial Yap/Taz are required for functional alveolar regeneration following acute lung injury

  • Text
  • PDF
Abstract

A hallmark of idiopathic pulmonary fibrosis (IPF) and other interstitial lung diseases is dysregulated repair of the alveolar epithelium. The Hippo pathway effector transcription factors YAP and TAZ are implicated as essential for type 1 and type 2 alveolar epithelial cell (AT1 and AT2) differentiation in the developing lung, yet aberrant activation of YAP/TAZ is a prominent feature of the dysregulated alveolar epithelium in IPF. In these studies, we sought to define the functional role of YAP/TAZ activity during alveolar regeneration. We demonstrated that Yap and Taz were normally activated in AT2 cells shortly after injury, and deletion of Yap/Taz in AT2 cells led to pathologic alveolar remodeling, failure of AT2-to-AT1 cell differentiation, increased collagen deposition, exaggerated neutrophilic inflammation, and increased mortality following injury induced by a single dose of bleomycin. Loss of Yap/Taz activity prior to an LPS injury prevented AT1 cell regeneration, led to intraalveolar collagen deposition, and resulted in persistent innate inflammation. These findings establish that AT2 cell Yap/Taz activity is essential for functional alveolar epithelial repair and prevention of fibrotic remodeling.

Authors

Gianluca T. DiGiovanni, Wei Han, Taylor P. Sherrill, Chase J. Taylor, David S. Nichols, Natalie M. Geis, Ujjal K. Singha, Carla L. Calvi, A. Scott McCall, Molly M. Dixon, Yang Liu, Ji-Hoon Jang, Sergey S. Gutor, Vasiliy V. Polosukhin, Timothy S. Blackwell, Jonathan A. Kropski, Jason J. Gokey

×

Figure 4

Loss of YAP/TAZ prior to LPS-induced lung injury leads to failed alveolar regeneration and increased collagen deposition.

Options: View larger image (or click on image) Download as PowerPoint
Loss of YAP/TAZ prior to LPS-induced lung injury leads to failed alveola...
(A) Schematic of LPS lung injury model in which mice were treated with tamoxifen 2 weeks prior to LPS lung injury. (B) Masson’s trichrome staining of WT and YTdel mice treated with saline or 3, 7, or 28 days after LPS injury. n = 6 mice per group. (C) Quantification of injured lung area in WT and YTdel mice 3 to 28 days after LPS. (D) Immunofluorescence analysis of Hopx+ (white) AT1 cells and Sp-C+ (green) AT2 cells 7 days after LPS injury. (E and F) Quantification of Hopx+ and Sp-C+ cells in WT or YTdel lungs treated with saline or LPS at 7 or 28 days after injury; n = 5 mice per group. Statistics were performed using 1-way ANOVA and Tukey’s post hoc comparison. Scale bars: 50 µm (D), 200 µm (B).

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts